Page 5 - Dr Lal Pathlabs
Dr Lal PathLabs hits 52-week low after block deals
The stock slipped 6.5% to Rs 780 after two per cent of total equity changed hands on NSE and BSE.
 "Dr Lal PathLabs hits 52-week low after block deals")
Dr Lal PathLabs eyes growth via acquisitions
Dr Lal PathLabs is focusing on 'inorganic growth'
Dr Lal Pathlabs' strong brand and network keep it in the pink of health
Dr Lal Pathlabs is Business Standard Star SME of the Year 2016
 "Dr Lal Pathlabs' strong brand and network keep it in the pink of health")
Gradual sales recovery for Dr Lal PathLabs
December quarter could come under pressure, but growth set to improve from March quarter
 "Gradual sales recovery for Dr Lal PathLabs")
Dr. Lal PathLabs hits new high; zooms 100% from issue price
The stock hit a new high of Rs 1,114, rallied 21% in past two trading sessions from Rs 922 on the BSE.
 "Dr. Lal PathLabs hits new high; zooms 100% from issue price")
Dr Lal PathLabs faces pricing pressure, margin erosion
In its annual report, the company raised concerns of pricing control at the time of epidemics
 "Dr Lal PathLabs faces pricing pressure, margin erosion")
Dr Lal PathLabs eyeing 18% growth in FY17
The company had posted a revenue of Rs 791.3 crore for the fiscal year 2015-16
 "Dr Lal PathLabs eyeing 18% growth in FY17")
Dr Lal PathLabs Q4 profit up 20% at Rs 34 cr
Total income from operations up 15% Rs 198 cr for the quarter; full-year profit up 38% at Rs 132 cr
 "Dr Lal PathLabs Q4 profit up 20% at Rs 34 cr")
Dr. Lal PathLabs hits highest level since listing
The stock has soared 11% to Rs 947, its highest level since listing on the bourses in December last year
 "Dr. Lal PathLabs hits highest level since listing")